Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Climb Bio Inc 20 William Street Suite 145 Wellesley Hills MA 02481 USA

www.eliemtx.com Employees: 18 P: 866-857-2596

Sector:

Medical

Description:

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Key Statistics

Overview:

Market Capitalization, $K 287,736
Enterprise Value, $K 200,506
Shares Outstanding, K 68,184
Float, K 67,639
% Float 99.20%
Short Interest, K 1,817
Short Float 2.66%
Days to Cover 1.11
Short Volume Ratio 0.38
% of Insider Shareholders 0.80%
% of Institutional Shareholders 69.76%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -73,900 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -12,890 K
EBIT, $ -59,500 K
EBITDA, $ -60,260 K

Growth:

1-Year Return 122.56%
3-Year Return 9.90%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 11/06/25
Next Earnings Date 03/24/26
Earnings Per Share ttm -0.76
EPS Growth vs. Prev Qtr -46.15%
EPS Growth vs. Prev Year -46.15%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CLYM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -26.43%
Return-on-Assets % -25.61%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.62
Book Value/Share 2.61
Interest Coverage -3.61
60-Month Beta -0.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar